Skip to main content

Advertisement

SpringerLink
Log in

Ranibizumab versus dexamethasone implant for central retinal vein occlusion: the RANIDEX study

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To compare intravitreal ranibizumab and dexamethasone implant in patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO).

Methods

Participants were 42 treatment naive patients with ME due to CRVO, who received either intravitreal 0.5 mg ranibizumab (n = 25) or intravitreal 0.7 mg dexamethasone implant (n = 17). The main outcomes included the mean change in best corrected visual acuity (BCVA) and central subfield thickness (CST) at month 12 compared to baseline in the two groups.

Results

At month 12, there was no statistically significant difference in BCVA and CST change between the two groups. However, there was recurrence in ME at month 5 in the dexamethasone group.

Conclusions

Both ranibizumab and dexamethasone implant were found to be safe and effective at the 12-month follow-up in patients with ME secondary to CRVO. Since there was a recurrence in ME at month 5 in the dexamethasone group, we suggested that intravitreal injection of dexamethasone implant should be potentially administered sooner than 6 months.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, Kowalski JW, Nguyen H, Wong TY, International Eye Disease Consortium (2010) The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 117:313–319

    Article  PubMed  PubMed Central  Google Scholar 

  2. Yau JW, Lee P, Wong TY, Best J, Jenkins A (2008) Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management. Intern Med J 38:904–910

    Article  CAS  PubMed  Google Scholar 

  3. Deobhakta A, Chang LK (2013) Inflammation in retinal vein occlusion. Int J Inflam 2013:438412

    Article  PubMed  PubMed Central  Google Scholar 

  4. Noma H, Funatsu H, Mimura T, Harino S, Hori S (2009) Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Ophthalmology 116:87–93

    Article  PubMed  Google Scholar 

  5. McIntosh RL, Rogers SL, Lim L, Cheung N, Wang JJ, Mitchell P, Kowalski JW, Nguyen HP, Wong TY (2010) Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 117:1113–1123

    Article  PubMed  Google Scholar 

  6. Chatziralli I, Nicholson L, Sivaprasad S, Hykin P (2015) Intravitreal steroid and anti-vascular endothelial growth agents for the management of retinal vein occlusion: evidence from randomized trials. Expert Opin Biol Ther 15:1685–1697

    Article  CAS  PubMed  Google Scholar 

  7. Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY, Rubio RG (2011) Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 118:2041–2049

    Article  PubMed  Google Scholar 

  8. Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, Lai P (2012) Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 119:802–809

    Article  PubMed  Google Scholar 

  9. Campochiaro PA, Sophie R, Pearlman J, Brown DM, Boyer DS, Heier JS, Marcus DM, Feiner L, Patel A; RETAIN Study Group (2014) Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology 121:209–219.

  10. Farinha C, Marques JP, Almeida E, Baltar A, Santos AR, Melo P, Costa M, Figueira J, Cachulo ML, Pires I, Silva R (2015) Treatment of retinal vein occlusion with Ranibizumab in clinical practice: longer-term results and predictive factors of functional outcome. Ophthalmic Res 55:10–18

    Article  PubMed  Google Scholar 

  11. Chang-Lin JE, Attar M, Acheampong AA, Robinson MR, Whitcup SM, Kuppermann BD, Welty D (2011) Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci 52:80–86

    Article  CAS  PubMed  Google Scholar 

  12. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM, OZURDEX GENEVA Study Group (2010) Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117:1134–1146

    Article  PubMed  Google Scholar 

  13. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jiao J, Li XY, Whitcup SM, Ozurdex GENEVA Study Group (2011) Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 118:2453–2560

    Article  PubMed  Google Scholar 

  14. Maggio E, Polito A, Guerriero M, Pertile G (2014) Intravitreal dexamethasone implant for macular edema secondary to retinal vein occlusion: 12-month follow-up and prognostic factors. Ophthalmologica 232:207–215

    Article  CAS  PubMed  Google Scholar 

  15. Ferrini W, Ambresin A (2013) Intravitreal dexamethasone implant for the treatment of macular edema after retinal vein occlusion in a clinical setting. Klin Monatsbl Augenheilkd 230:423–426

    Article  CAS  PubMed  Google Scholar 

  16. Bezatis A, Spital G, Höhn F, Maier M, Clemens CR, Wachtlin J, Lehmann F, Hattenbach LO, Feltgen N, Meyer CH (2013) Functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion: a 6-month follow-up -- the SOLO study. Acta Ophthalmol 91:e340–e347

    Article  PubMed  Google Scholar 

  17. Hoerauf H, Feltgen N, Weiss C, Paulus EM, Schmitz-Valckenberg S, Pielen A, Puri P, Berk H, Eter N, Wiedemann P, Lang GE, Rehak M, Wolf A, Bertelmann T, Hattenbach LO, COMRADE-C Study Group (2016) Clinical efficacy and safety of Ranibizumab versus dexamethasone for central retinal vein occlusion (COMRADE C): a European label study. Am J Ophthalmol 169:258–267

    Article  CAS  PubMed  Google Scholar 

  18. Chiquet C, Dupuy C, Bron AM, Aptel F, Straub M, Isaico R, Romanet JP, Creuzot-Garcher C (2015) Intravitreal dexamethasone implant versus anti-VEGF injection for treatment-naïve patients with retinal vein occlusion and macular edema: a 12-month follow-up study. Graefes Arch Clin Exp Ophthalmol 253:2095–2102

    Article  CAS  PubMed  Google Scholar 

  19. Mayer WJ, Hadjigoli A, Wolf A, Herold T, Haritoglou C (2015) Comparison of intravitreal dexamethasone implant versus intravitreal Ranibizumab as a first-line treatment of macular Oedema due to retinal vein occlusion. Klin Monatsbl Augenheilkd 232:1289–1296

    Article  CAS  PubMed  Google Scholar 

  20. Gado AS, Macky TA (2014) Dexamethasone intravitreous implant versus bevacizumab for central retinal vein occlusion-related macular oedema: a prospective randomized comparison. Clin Exp Ophthalmol 42:650–655

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 2nd Department of Ophthalmology, “Attikon” Hospital, National and Kapodistrian University of Athens, Athens, Greece

    Irini Chatziralli & Panagiotis Theodossiadis

  2. 1 Rimini Street, Haidari, 12462, Athens, Greece

    Irini Chatziralli

  3. 2nd Department of Ophthalmology, Henry Dunant Hospital, Athens, Greece

    George Theodossiadis

  4. Medical Retina Department, Korgialeneio Benakeio, Red Cross Hospital, Athens, Greece

    Stamatina A. Kabanarou & Tina Xirou

  5. 2nd Department of Ophthalmology, Ophthalmiatrion Athinon, Athens, Greece

    Efstratios Parikakis & Panagiotis Mitropoulos

Authors
  1. Irini Chatziralli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George Theodossiadis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stamatina A. Kabanarou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Efstratios Parikakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tina Xirou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Panagiotis Mitropoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Panagiotis Theodossiadis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Irini Chatziralli.

Ethics declarations

Funding

No funding was received for this research.

Conflict of interest

All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria, educational grants, or other equity interest), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

Ethical approval

The study adhered to the Declaration of Helsinki and was approved by the institutional review board as a retrospective study. Written informed consent was obtained from all participants.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chatziralli, I., Theodossiadis, G., Kabanarou, S.A. et al. Ranibizumab versus dexamethasone implant for central retinal vein occlusion: the RANIDEX study. Graefes Arch Clin Exp Ophthalmol 255, 1899–1905 (2017). https://doi.org/10.1007/s00417-017-3719-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-017-3719-5

Keywords

Search

Navigation